Mike Burg was producing a primetime concert special for FOX in 2001 when he received a cancer diagnosis from his doctor in North Carolina. A biopsy showed stage III Hodgkin lymphoma, and what followed was chemotherapy, radiation, a recurrence, and eventually a cross-country trip to Omaha that Burg still makes a quarter-century later.
Burg went through chemo and radiation before his Hodgkin's lymphoma recurred late in 2002, according to Nebraska Medicine. His doctor in North Carolina referred him to a specialist more than 1,000 miles away, telling him, according to that same account, “You need to go to Dr. Julie Vose at the Nebraska Medical Center.” Burg recalled the moment the diagnosis first landed, telling WOWT, “We know we think it's cancer, but we think it's treatable. And those words just rang into my ears.”
Vose, an oncology and hematology physician who directs the Lymphoma Research Group at the University of Nebraska Medical Center, recommended a stem cell transplant using Burg's own genetically engineered cells. The procedure and recovery kept Burg in Omaha for two months, away from his family back in North Carolina, the WOWT report notes. Burg later explained his decision to travel so far for treatment: “The best in the nation is Dr. Julie Vose at University of Nebraska Medical Center... if you have a Mercedes, you want to go to the dealership.”
A Husker Game Against Doctors' Orders
Even mid-recovery, Burg wasn't content to sit still. He went against doctors' orders to attend a Nebraska football game against Utah State in Lincoln, according to the station's report. It's a detail that captures the restlessness of a man used to working in live television production rather than hospital rooms, and it stuck with him enough to resurface decades later when recounting his treatment.
The stem cell transplant worked, Burg has said, and per Vose, he has been in remission continuously for 20 years since. Vose told the outlet the chances that his Hodgkin's lymphoma would recur at this point are “very minimal, if not zero,” and she described his recovery as extraordinary to watch.
From Network TV to Cancer Advocacy
Burg's brush with cancer reshaped his career path. He left network entertainment work and moved into advocacy, producing the ABC special Frosted Pink in 2007 and working with national cancer organizations, per the same account. Atrium Health, which also chronicled his diagnosis, notes that cancer treatment has evolved substantially since Burg's own case, with specialists now favoring Atrium Health describing “a combination of immunotherapy with chemotherapy” rather than chemotherapy alone, following a large phase 3 clinical trial that helped establish that newer first-line approach for advanced classic Hodgkin lymphoma.
The National Cancer Institute notes that treatment of advanced classic Hodgkin lymphoma in adults may include combination chemotherapy with or without immunotherapy drugs like nivolumab or targeted therapy such as brentuximab vedotin, according to the National Cancer Institute. Research published on PMC indicates the overall prognosis for Hodgkin lymphoma is excellent, with 90% of early-stage patients and 70 to 80% of advanced-stage patients cured by frontline treatment, though up to 30% of patients may have relapsed or refractory disease, per a study on PMC.
Still Flying Back to Nebraska
Burg is now based in Los Angeles, where cancer centers are closer to home, but he said he still flies back to Omaha for his care. “I would never, ever go anywhere else but that place,” he said. “I just feel safe there.” That loyalty, 25 years and a continent removed from his original diagnosis, reflects a level of trust Burg has said gave him a greater appreciation of what cancer patients go through.
Vose said Burg's continued connection to Nebraska Medicine benefits other patients, and doctors there have said his 25-year milestone shows that people from anywhere in the country can continue receiving care in Nebraska. The health system's Blood and Bone Marrow Transplant program has averaged 150 transplants a year since its inception in 1983, according to Nebraska Medicine, which also says hundreds of patients from across the globe select its specialists for cancer treatment and transplantation.
Vose's own career has drawn some varying descriptions in UNMC's own materials. A faculty biography on the university's website says she served as president of the American Society of Clinical Oncology in 2016 and has published more than 400 manuscripts on lymphoma and related conditions, while a 2025 UNMC newsroom article states she served as ASCO president in 2015 and has published nearly 600 papers, according to UNMC's newsroom. Either way, Vose became director of the Lymphoma Research Group at UNMC effective November 1, 2025.
